

# Pablo R Moya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/674139/publications.pdf>

Version: 2024-02-01

39  
papers

1,441  
citations

430874

18  
h-index

330143

37  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2120  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 701-708.	2.1	2
2	Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 4615-4637.	5.4	85
3	Altered Grooming Syntax and Amphetamine-Induced Dopamine Release in EAAT3 Overexpressing Mice. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 661478.	3.7	8
4	Lack of Association between the IL6R Gene Asp358Ala Variant (rs2228145), IL-6 Plasma Levels, and Treatment Resistance in Chilean Schizophrenic Patients Treated with Clozapine. <i>Schizophrenia Research and Treatment</i> , 2019, 2019, 1-5.	1.5	3
5	The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder. <i>Frontiers in Pharmacology</i> , 2019, 10, 1362.	3.5	11
6	Ketamine-Treatment During Late Adolescence Impairs Inhibitory Synaptic Transmission in the Prefrontal Cortex and Working Memory in Adult Rats. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 372.	3.7	12
7	Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression. <i>Neuropsychopharmacology</i> , 2019, 44, 1163-1173.	5.4	27
8	Esquizofrenia resistente: Definiciones e Implicancias del concepto de Esquizofrenia Resistente a tratamiento. <i>Revista Chilena De Neuro-Psiquiatria</i> , 2019, 57, 394-404.	0.1	1
9	Dennis Luke Murphy, M.D. (1936–2017). <i>Genes, Brain and Behavior</i> , 2018, 17, e12455.	2.2	1
10	Neonatal exposure to oestradiol increases dopaminergic transmission in nucleus accumbens and morphine-induced conditioned place preference in adult female rats. <i>Journal of Neuroendocrinology</i> , 2018, 30, e12574.	2.6	19
11	3D similarities between the binding sites of monoaminergic target proteins. <i>PLoS ONE</i> , 2018, 13, e0200637.	2.5	5
12	Amphetamine treatment affects the extra-hypothalamic vasopressinergic system in a sex- and nucleus-dependent manner. <i>Journal of Neuroendocrinology</i> , 2017, 29, .	2.6	6
13	ABCB1 and ABCC2 gene polymorphisms and response to anticonvulsant therapy in patients with idiopathic epilepsy from the neurology clinics at Van Buren Hospital. <i>Journal of the Neurological Sciences</i> , 2017, 381, 684-685.	0.6	0
14	Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice. <i>Biological Research</i> , 2017, 50, 29.	3.4	7
15	Connecting Synaptic Activity with Plasticity-Related Gene Expression: From Molecular Mechanisms to Neurological Disorders. <i>Neural Plasticity</i> , 2016, 2016, 1-3.	2.2	3
16	Programming of Dopaminergic Neurons by Neonatal Sex Hormone Exposure: Effects on Dopamine Content and Tyrosine Hydroxylase Expression in Adult Male Rats. <i>Neural Plasticity</i> , 2016, 2016, 1-11.	2.2	14
17	Mini-revisi3n: Variantes gen3ticas del transportador de serotonina en trastornos neuropsiqui3tricos. <i>Revista Chilena De Neuro-Psiquiatria</i> , 2014, 52, 115-122.	0.1	3
18	Improving Amphetamine Therapeutic Selectivity: N,N-dimethyl-3-methyl-5-(2-methyl-5-oxo-1H-imidazol-2-yl)pentan-2-amine has Dopaminergic Effects and does not Produce Aortic Contraction. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 395-399.	2.5	4

#	ARTICLE	IF	CITATIONS
19	Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans. <i>Pharmacogenomics Journal</i> , 2013, 13, 551-557.	2.0	14
20	Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2013, 368, 20120435.	4.0	84
21	Meta-analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene <i>SLC1A1</i> . <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 367-379.	1.7	83
22	miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 621-629.	2.1	51
23	Rare missense neuronal cadherin gene (CDH2) variants in specific obsessive-compulsive disorder and Tourette disorder phenotypes. <i>European Journal of Human Genetics</i> , 2013, 21, 850-854.	2.8	38
24	Common and rare alleles of the serotonin transporter gene, <i>SLC6A4</i> , associated with Tourette's disorder. <i>Movement Disorders</i> , 2013, 28, 1263-1270.	3.9	44
25	4-Methylthioamphetamine Increases Dopamine in the Rat Striatum and has Rewarding Effects <i>In Vivo</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 371-379.	2.5	12
26	In a Model of Batten Disease, Palmitoyl Protein Thioesterase-1 Deficiency Is Associated with Brown Adipose Tissue and Thermoregulation Abnormalities. <i>PLoS ONE</i> , 2012, 7, e48733.	2.5	12
27	Genetic contributions to obsessive-compulsive disorder (OCD) and OCD-related disorders. , 2012, , 121-133.		4
28	Lentivirally mediated GSK-3 $\beta$ silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 711-717.	2.1	44
29	Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G $\beta$ -G and G $\beta$ -E differences in health and disease. <i>Current Opinion in Pharmacology</i> , 2011, 11, 3-10.	3.5	82
30	A non-synonymous polymorphism in galactose mutarotase (GALM) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study. <i>Molecular Psychiatry</i> , 2011, 16, 584-585.	7.9	19
31	Altered 5-HT $2C$ receptor agonist-induced responses and 5-HT $2C$ receptor RNA editing in the amygdala of serotonin transporter knockout mice. <i>BMC Pharmacology</i> , 2011, 11, 3.	0.4	28
32	Increased gene expression of diacylglycerol kinase eta in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1127-1128.	2.1	38
33	A Haplotype Containing Quantitative Trait Loci for SLC1A1 Gene Expression and Its Association With Obsessive-Compulsive Disorder. <i>Archives of General Psychiatry</i> , 2009, 66, 408.	12.3	131
34	<i>N,N</i> -dimethylthioamphetamine and methylthioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant <i>in vitro</i> efficacy for the induction of transporter-mediated 5-HT release and currents. <i>Journal of Neurochemistry</i> , 2008, 105, 1770-1780.	3.9	19
35	How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. <i>Neuropharmacology</i> , 2008, 55, 932-960.	4.1	199
36	A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. <i>Human Molecular Genetics</i> , 2007, 17, 717-723.	2.9	119

#	ARTICLE	IF	CITATIONS
37	Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT) <sub>2A</sub> and 5-HT <sub>2C</sub> Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 1054-1061.	2.5	105
38	Pharmacological Identification of P2X <sub>1</sub> , P2X <sub>4</sub> and P2X <sub>7</sub> Nucleotide Receptors in the Smooth Muscles of Human Umbilical Cord and Chorionic Blood Vessels. <i>Placenta</i> , 2003, 24, 17-26.	1.5	31
39	Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors. <i>British Journal of Pharmacology</i> , 2002, 136, 510-519.	5.4	69